期刊文献+

川芎嗪联合前列地尔治疗背景性糖尿病视网膜病变疗效的临床观察 被引量:11

The Effectiveness of Ligustrazine Combined with Alprostadil Treatment on Background Diabetic Retinopathy
原文传递
导出
摘要 目的:探讨川芎嗪(Ligustrazine)联合前列地尔(Alprostadil)治疗背景性糖尿病视网膜病变(Diabetic retinopathy,DR)的作用与疗效。方法:收集近年我院糖尿病伴背景性DR共73例(112只眼),分别按治疗中应用川芎嗪联合前列地尔或拜阿司匹林分为治疗组与对照组,比较两组治疗前后患者眼底病变改善情况。结果:川芎嗪联合前列地尔的治疗组疗效比拜阿司匹林的对照组好;眼底荧光检查表明,治疗组眼底病变改善明显好于对照组,差异显著(P<0.05)。结论:川芎嗪联合前列地尔对DR有较好的疗效。 Objective: Diabetic retinopathy(DR) is a blinding oculopathy which seriously influence human health and the leading cause of blind in old patient beyond the age of 50 in China.This study aimed to observe the therapy effectiveness of Ligustrazine combined with Alprostadil for background DR and discuss the mechanism.Methods:Select background DR patients(n=73).To treat the retinopathy eyes(n=112),we set treatment group by using Ligustrazine combined with Alprostadil and control group by using Ligustrazaine and Aspirin.Compare the eyeground pathological changes before and after treatment.Results:Treatment using Ligustrazine combined with Alprostadil had a better performance after thyrapy compared before than Ligustrazaine and Aspirin.The overall efficacy was 68.97% in treatment group,while 38.89% in control group.Fluorescein fundus angiography showed that improvement for treatment was obvious better than control,(P〈0.05).Conclusion:Ligustrazine combined with Alprostadil therapy is effective for treat diabetic background retinopathy.Conservative medical management plays an important role in DR.
出处 《现代生物医学进展》 CAS 2012年第14期2713-2715,共3页 Progress in Modern Biomedicine
关键词 川芎嗪 前列地尔 背景性糖尿病视网膜病变 Ligustrazine; Alprostadil; Background diabetic retinopathy
  • 相关文献

参考文献6

二级参考文献26

共引文献278

同被引文献64

  • 1李瑞杰.美国心脏病学会和美国心脏协会2005成人慢性心力衰竭诊断与治疗指南(连载1)[J].临床荟萃,2006,21(11):761-764. 被引量:36
  • 2丁友梅,雷亚宁.川芎嗪对糖尿病大鼠视网膜的保护作用[J].山东医药,2006,46(29):18-19. 被引量:9
  • 3卢娜,王宝英,魏林郁,杜爱林,李东亮,李超.低氧预处理对大鼠缺血-再灌注性脑损伤中凋亡及Fas和Fas-L蛋白表达的影响[J].中国临床康复,2006,10(46):120-122. 被引量:10
  • 4李为民,刘巍.2005年中国高血压防治指南评介[J].中国实用内科杂志,2007,27(12):899-902. 被引量:73
  • 5Satoko Shiyanagi,Tadaharu Okazaki,Hiromichi Shoji,Toshiaki Shimizu,Toshitaka Tanaka,Satoru Takeda,Kazunari Kawashima,Geoffrey J. Lane,Atsuyuki Yamataka.Management of pulmonary hypertension in congenital diaphragmatic hernia: nitric oxide with prostaglandin-E1 versus nitric oxide alone[J]. Pediatric Surgery International . 2008 (10)
  • 6Cristina Giannattasio,MariaRosa Pozzi,Marco Gradinali,Elisabetta Montemerlo,Francesca Citterio,Silvia Maestroni,Elena Fantini,Monica Failla,Maria Robuschi,Salvatore Bianco,Giuseppe Mancia.Effects of prostaglandin E1α cyclodestrin treatment on endothelial dysfunction in patients with systemic sclerosis[J]. Journal of Hypertension . 2007 (4)
  • 7Zheng YF, He MG, Congdon Nathan. The worldwide epidemic of diabetic retinopathy [ J ]. Indian J Ophthalrnol, 2012,60 : 428 - 431.
  • 8Ko F, Vitale S, Chou CF, et al. Prevalence of nonrefractive visual impairment in US adults and associated risk factors, 1999 -2002 and 2005 - 2008 [ J]. JAMA, 2012,308:2361 - 2368.
  • 9Katakami N, Matsuhisa M, Kaneto H, et al. Monocyte chemoat- tractant protein - 1 ( MCP - 1 ) gene polymorphism as potential risk factor for diabetic retinopathy in Japanese patients with type 2 diabe- tes[ J]. Diabetes Res Clin Pract , 2010,89:9-12.
  • 10Bai Y, Ma JX, Gao J, et al. Mtiller cell -derived VEGF is a sig- nificant contributor to retinal nevascularization [ J ]. J Pathol, 2009,219:446 -454.

引证文献11

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部